Avacta Group (AVCT) investor relations material

Research and development progress

• First patient dosed in FOCUS-01 Phase 1 trial for AVA6103 after IND clearance; enrollment ongoing.

• Favorable preclinical data for AVA6103 compared to leading antibody drug conjugates presented at AACR 2026.

• Updated Phase 1a/1b data for AVA6000 in salivary gland cancers showed encouraging efficacy and favorable cardiac safety, leading to dose cap removal.

• Gen Three (AVA6207) demonstrated dual payload technology with sustained release in updated in vivo data.

• Intellectual property portfolio expanded with increased filings.

Financial and corporate highlights

• Raised £10 million in an oversubscribed placing and subscription in March 2026, extending cash runway into early Q1 2027.

• Secured an additional £9 million from institutional investors and shareholders in June 2026, reducing debt and strengthening the balance sheet.

• Total gross proceeds raised in the last 18 months reached £41.5 million.

• Richard Hughes appointed as Non-Executive Chairman; a new Deputy Chairman/Senior Independent Director to be announced.

Outlook for 2H 2026

• Initial clinical data from AVA6103 program expected in late H2 2026.

• Further AVA6000 clinical data to be presented at BIO International and a medical congress in Q3 2026.

• AVA6207 payload and clinical candidate selection anticipated in H2 2026.

• Ongoing discussions for potential partnering of first, second, and third generation assets.